Skip to content

Repligen RGEN Net Investment in Lease

Net Investment in Lease at other companies

TEC
Bio-TechneTECH
Revvity logo
RevvityRVTY
Danaher logo
DanaherDHR
Agilent Technologies logo
Agilent TechnologiesA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's net investment in lease?
Repligen (RGEN) reported net investment in lease of $113.64M in Q1 2026.
How has Repligen's net investment in lease changed year-over-year?
Repligen's net investment in lease decreased by 12.4% year-over-year, from $129.67M to $113.64M.
What is the long-term trend for Repligen's net investment in lease?
Over 5 years (2020 to 2025), Repligen's net investment in lease has grown at a 36.6% compound annual growth rate (CAGR), from $25.18M to $119.54M.